Dexmedetomidine: pediatric pharmacology, clinical uses and safety

被引:71
|
作者
Su, Felice [1 ]
Hammer, Gregory B. [2 ,3 ]
机构
[1] Stanford Univ, Div Crit Care Med, Dept Pediat, Palo Alto, CA 94304 USA
[2] Stanford Univ, Sch Med, Dept Anesthesia, Stanford, CA 94305 USA
[3] Stanford Univ, Sch Med, Dept Pediat, Stanford, CA 94305 USA
关键词
alpha(2)-agonist; adverse effects; dexmedetomidine; indications; pediatrics; sedation; INTENSIVE-CARE-UNIT; DOSE DEXMEDETOMIDINE; CARDIAC-SURGERY; ALPHA(2A)-ADRENERGIC RECEPTOR; HYPNOTIC RESPONSE; INTRAVENOUS DEXMEDETOMIDINE; AGONIST DEXMEDETOMIDINE; INFLAMMATORY RESPONSES; SEVOFLURANE ANESTHESIA; PROCEDURAL SEDATION;
D O I
10.1517/14740338.2010.512609
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Importance of the field: Dexmedetomidine is an alpha(2)-adrenoceptor agonist with sedative, anxiolytic and analgesic properties. It is used off-label in pediatric patients due to its efficacy and lack of adverse respiratory effects. Dexmedetomidine may cause severe circulatory complications in adults. Despite its popularity, the safety of dexmedetomidine in the pediatric population has not been extensively studied. Areas covered in this review: This article reviews the current literature (up to 2010) focusing on applications and safety of dexmedetomidine administered to pediatric patients. What the reader will gain: Dexmedetomidine is a useful sedative and anxiolytic drug in the pediatric intensive care unit as well as during diagnostic and therapeutic procedures. Deleterious effects of dexmedetomidine include hypotension and bradycardia. Additionally, hypertension may occur during the "loading dose" or with high infusion rates. Few studies have been performed to evaluate the safety of dexmedetomidine in pediatrics. The development of tolerance and withdrawal has not been studied in children. Take home message: Despite its favorable respiratory profile, dexmedetomidine may cause deleterious cardiovascular effects. Close monitoring of circulatory dynamics and judicious titration is recommended. Further studies are needed to better define adverse effects following long-term infusions as well as in special populations such as pre-term infants.
引用
收藏
页码:55 / 66
页数:12
相关论文
共 50 条
  • [41] Clinical Pharmacology and Cardiovascular Safety of Naproxen
    Dominick J. Angiolillo
    Steven M. Weisman
    American Journal of Cardiovascular Drugs, 2017, 17 : 97 - 107
  • [42] Safety and Pharmacology of Oseltamivir in Clinical Use
    Regina Dutkowski
    Bharat Thakrar
    Enrico Froehlich
    Pia Suter
    Charles Oo
    Penny Ward
    Drug Safety, 2003, 26 : 787 - 801
  • [43] Pharmacology, toxicology and clinical safety of glycopyrrolate
    Chabicovsky, Monika
    Winkler, Swantje
    Soeberdt, Michael
    Kilic, Ana
    Masur, Clarissa
    Abels, Christoph
    TOXICOLOGY AND APPLIED PHARMACOLOGY, 2019, 370 : 154 - 169
  • [44] Safety and pharmacology of oseltamivir in clinical use
    Dutkowski, R
    Thakrar, B
    Froehlich, E
    Suter, P
    Oo, C
    Ward, P
    DRUG SAFETY, 2003, 26 (11) : 787 - 801
  • [45] Clinical Pharmacology and Cardiovascular Safety of Naproxen
    Angiolillo, Dominick J.
    Weisman, Steven M.
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2017, 17 (02) : 97 - 107
  • [46] PHARMACOLOGY, CLINICAL-PHARMACOLOGY AND POTENTIAL THERAPEUTIC USES OF THE SPECIFIC BRADYCARDIAC AGENT ALINIDINE
    HARRON, DWG
    SHANKS, RG
    EUROPEAN HEART JOURNAL, 1985, 6 (09) : 722 - 729
  • [47] Plumula Nelumbinis: A review of traditional uses, phytochemistry, pharmacology, pharmacokinetics and safety
    Chen, Sixuan
    Li, Xuping
    Wu, Junxuan
    Li, Jingyan
    Xiao, Mingzhu
    Yang, Ying
    Liu, Zhongqiu
    Cheng, Yuanyuan
    JOURNAL OF ETHNOPHARMACOLOGY, 2021, 266
  • [48] Clinical Pharmacology and Pharmacoepidemiology for Medication Safety in Clinical Settings
    Kawakami, Junichi
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2015, 135 (04): : 619 - 624
  • [49] BETA ADRENERGIC-BLOCKADE, 1972 - PHARMACOLOGY AND CLINICAL USES
    HARRISON, DC
    AMERICAN JOURNAL OF CARDIOLOGY, 1972, 29 (03): : 432 - &
  • [50] ETHICAL PROBLEMS IN PEDIATRIC, CLINICAL-PHARMACOLOGY
    GLADTKE, E
    MONATSSCHRIFT KINDERHEILKUNDE, 1983, 131 (01) : 2 - 5